In MM cells, inactivation of CK1α induces cell cycle arrest and overcomes the bone marrow stromal protection, indicating that lenalidomide-dependent degradation of CK1α may complement its anti-myeloma activity [33,34,35]. Here, CSNK1A1 is linked to Miyoshi myopathy.